Anxiety and Depression Comorbidity: Prevalence, Shared Mechanisms, Treatment Implications, and Prognosis

Comorbid anxiety and depressive disorders represent one of the most common clinical presentations in mental health care. Far from being an occasional diagnostic curiosity, co-occurring anxiety and depression is the modal presentation in both primary care and specialty mental health settings. The DSM-5-TR recognizes these as distinct diagnostic categories, yet their overlap is so pervasive that some researchers have argued they represent variations of a single underlying internalizing spectrum rather than truly independent conditions.

The clinical significance of this comorbidity cannot be overstated. Compared to either condition alone, comorbid anxiety and depression is associated with greater symptom severity, higher functional impairment, increased suicidality, poorer treatment response, more chronic illness course, and substantially elevated healthcare utilization. Understanding the bidirectional relationship between these disorders — including their shared neurobiology, overlapping phenomenology, and synergistic effects on prognosis — is essential for effective clinical management.

This article examines the evidence base for anxiety-depression comorbidity across multiple dimensions: epidemiological prevalence, neurobiological mechanisms, clinical presentation, treatment selection, and long-term outcomes. While the term "anxiety" encompasses multiple DSM-5-TR diagnoses (generalized anxiety disorder, social anxiety disorder, panic disorder, specific phobias, and agoraphobia), this article focuses primarily on generalized anxiety disorder (GAD) and major depressive disorder (MDD) as the prototypical comorbid pair, with discussion of other anxiety-depression combinations where data are available.

The epidemiological data on anxiety-depression comorbidity are striking in their consistency across studies, populations, and methodologies. Multiple large-scale epidemiological surveys have established that these conditions co-occur at rates far exceeding what chance alone would predict.

Prevalence of Depression in Anxiety Disorders

Among individuals with any anxiety disorder, lifetime comorbid major depression occurs in approximately 50–60% of cases. Data from the National Comorbidity Survey Replication (NCS-R) found that 57% of individuals with lifetime MDD also met criteria for at least one anxiety disorder. The rates vary by specific anxiety diagnosis:

• Generalized Anxiety Disorder (GAD): Approximately 60–70% of individuals with GAD will experience a comorbid major depressive episode during their lifetime. The 12-month comorbidity rate is approximately 40–50%. GAD and MDD co-occur so frequently that some investigators, notably Goldberg and others, have proposed they may represent a single disorder with varying presentations.
• Social Anxiety Disorder (SAD): Lifetime comorbid depression occurs in approximately 35–50% of individuals with SAD. The NCS-R found an odds ratio of 3.7 for comorbid MDD in SAD.
• Panic Disorder: Approximately 50–65% of individuals with panic disorder experience comorbid major depression at some point, with 12-month comorbidity rates around 30–40%.
• PTSD: While classified separately from anxiety disorders in DSM-5-TR, PTSD demonstrates among the highest comorbidity rates with MDD, estimated at 48–55% in epidemiological samples and higher in clinical populations.

Prevalence of Anxiety in Depression

The reverse direction is equally notable. Among individuals presenting with major depressive disorder, approximately 60–70% have at least one co-occurring anxiety disorder, and roughly 40–50% meet criteria for two or more anxiety diagnoses. The STAR*D trial, one of the largest effectiveness studies in depression treatment, found that nearly 53% of enrolled participants with MDD had a clinically significant comorbid anxiety disorder at baseline. Anxious depression — defined by various thresholds on anxiety rating scales — was present in an even larger proportion, approaching two-thirds of the sample.

Temporal Sequencing

A consistent epidemiological finding is the temporal precedence of anxiety over depression. In the majority of comorbid cases — approximately 65–75% — the anxiety disorder has an earlier age of onset than the depressive disorder. Data from the NCS-R show that primary anxiety disorders typically precede the onset of major depression by a median of approximately 10–15 years. This pattern holds across multiple anxiety subtypes and has been replicated in prospective longitudinal studies. It has led to the hypothesis that chronic, untreated anxiety may serve as a developmental risk factor or prodrome for subsequent depression, potentially through mechanisms involving chronic stress exposure, behavioral avoidance, and neurobiological sensitization.

However, the reverse pathway also exists: approximately 15–20% of comorbid cases feature depression preceding anxiety onset, and in 10–20% of cases, both conditions appear to emerge concurrently. These temporal patterns have implications for prevention, suggesting that effective early treatment of childhood and adolescent anxiety disorders may reduce the subsequent incidence of depression.

The high comorbidity between anxiety and depressive disorders is not merely a statistical artifact of overlapping diagnostic criteria. It reflects substantial shared neurobiological substrates that predispose to both conditions and mediate their interaction.

Monoamine Systems

Both anxiety and depression involve dysregulation of serotonergic (5-HT) and noradrenergic (NE) neurotransmitter systems. The locus coeruleus–norepinephrine (LC-NE) system, which governs arousal and threat vigilance, shows hyperactivity in anxiety states and altered function in depression. Serotonergic projections from the dorsal raphe nucleus to the amygdala, prefrontal cortex, and hippocampus modulate both anxious apprehension and depressive mood regulation. The convergence of these systems explains why serotonin-norepinephrine reuptake inhibitors (SNRIs) and selective serotonin reuptake inhibitors (SSRIs) demonstrate efficacy across both disorder categories.

The serotonin transporter gene (5-HTTLPR) short allele has been associated with both increased anxiety traits and vulnerability to depression following stress, though the gene-by-environment interaction findings from the original Caspi et al. (2003) study have shown mixed replication. More robust evidence comes from genome-wide association studies (GWAS) demonstrating substantial genetic correlation (r_g ≈ 0.70–0.80) between MDD and GAD, suggesting a largely shared genetic architecture.

HPA Axis Dysregulation

The hypothalamic-pituitary-adrenal (HPA) axis, the body's primary stress response system, shows characteristic abnormalities in both conditions. Chronic anxiety is associated with sustained cortisol elevation and impaired negative feedback via glucocorticoid receptor downregulation. Prolonged HPA axis hyperactivation may eventually produce the flattened diurnal cortisol curves and impaired cortisol awakening response seen in chronic depression. This allostatic load model provides a plausible biological pathway for the common clinical observation that sustained anxiety precedes and transitions into depressive episodes.

Corticotropin-releasing hormone (CRH), the primary driver of the HPA axis, acts as a neuromodulator in the amygdala and bed nucleus of the stria terminalis (BNST), regions critical for sustained anxiety states. Elevated CRH levels in cerebrospinal fluid have been documented in both MDD and anxiety disorders, representing a shared pathophysiological mechanism.

Neural Circuit Abnormalities

Functional neuroimaging studies have identified overlapping and distinct neural circuit abnormalities in anxiety and depression:

• Amygdala hyperreactivity: Exaggerated amygdala responses to threat-relevant stimuli are characteristic of both conditions. In anxiety, this hyperreactivity is most pronounced for ambiguous or uncertain threats; in depression, it extends to sad and negatively valenced stimuli.
• Prefrontal cortex (PFC) dysfunction: Both conditions involve impaired top-down regulation by the dorsolateral and ventromedial PFC over limbic structures. In depression, hypoactivation of the left dorsolateral PFC is particularly prominent. In anxiety, the ventromedial PFC shows reduced capacity to extinguish conditioned fear responses.
• Default mode network (DMN) hyperconnectivity: The DMN, associated with self-referential processing and rumination, shows increased functional connectivity in both depression (associated with depressive rumination) and GAD (associated with worry). The shared involvement of the DMN may underlie the cognitive overlap between depressive rumination and anxious worry.
• Anterior cingulate cortex (ACC): The subgenual ACC (sgACC, Brodmann area 25) is implicated in both conditions, showing metabolic hyperactivity in treatment-resistant depression and altered function in anxiety states. The dorsal ACC, involved in error monitoring and conflict detection, shows hyperactivation in anxiety disorders.

GABA and Glutamate Systems

GABAergic deficits have been documented in both anxiety and depression. Magnetic resonance spectroscopy (MRS) studies show reduced cortical GABA concentrations in MDD and in GAD. Glutamate, the brain's primary excitatory neurotransmitter, shows elevated levels in anxiety states and dysregulated signaling in depression. The efficacy of ketamine (an NMDA glutamate receptor antagonist) in rapidly alleviating both depressive and anxious symptoms supports the role of glutamatergic dysfunction as a shared mechanism.

Inflammatory Pathways

Elevated pro-inflammatory cytokines — particularly interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP) — have been identified in both MDD and anxiety disorders. Peripheral inflammation can cross the blood-brain barrier, activate microglia, and alter tryptophan metabolism via the kynurenine pathway, reducing serotonin synthesis while increasing neurotoxic quinolinic acid. This neuroinflammatory cascade may contribute to the overlapping neurobiology of anxiety and depression, particularly in the context of chronic stress.

The co-occurrence of anxiety and depression produces a clinical phenotype that is qualitatively different from either condition alone — not simply the sum of two symptom lists, but a distinct clinical entity with unique features and challenges.

Symptom Severity and Functional Impairment

Comorbid anxiety-depression is consistently associated with greater overall symptom severity compared to either condition in isolation. Studies using the Hamilton Depression Rating Scale (HAM-D) and the Hamilton Anxiety Rating Scale (HAM-A) show that comorbid patients score higher on both scales than patients with either disorder alone. Functional impairment, measured by instruments such as the Sheehan Disability Scale or the WHO Disability Assessment Schedule (WHODAS), is significantly greater in comorbid presentations, with effect sizes in the moderate-to-large range (Cohen's d ≈ 0.5–0.8) compared to single-disorder groups.

Suicidality

Perhaps the most clinically critical consequence of comorbidity is elevated suicide risk. The combination of hopelessness (a cognitive hallmark of depression) with agitation, panic, and impulsivity (features amplified by comorbid anxiety) creates a particularly dangerous clinical picture. Research from the NCS-R and other datasets indicates that comorbid anxiety-depression approximately doubles the risk of suicide attempts compared to MDD alone. Panic attacks, whether part of a formal panic disorder diagnosis or occurring in the context of other anxiety disorders, are an independent risk factor for suicidal behavior in depressed patients. The STAR*D dataset confirmed that anxious depression was associated with increased suicidal ideation at baseline.

Somatic Symptom Burden

Comorbid presentations are marked by a higher burden of somatic symptoms: headaches, gastrointestinal distress, muscle tension, fatigue, dizziness, chest tightness, and chronic pain. This somatic symptom load complicates differential diagnosis, increases healthcare utilization, and frequently leads to extensive medical workups before psychiatric evaluation. Primary care studies suggest that patients with comorbid anxiety-depression have 2–3 times the rate of medically unexplained physical symptoms compared to those with depression alone.

Clinical Vignette: Diagnostic Complexity

A 34-year-old woman presents to primary care reporting persistent fatigue, difficulty concentrating, insomnia, and a "constant knot" in her stomach over the past six months. She endorses low mood and loss of interest in activities she previously enjoyed. She also describes uncontrollable worry about her finances, her children's wellbeing, and her job performance, accompanied by muscle tension and restlessness. On the PHQ-9, she scores 18 (moderately severe depression). On the GAD-7, she scores 16 (severe anxiety). She meets DSM-5-TR criteria for both MDD and GAD. Her insomnia, fatigue, difficulty concentrating, and restlessness could be attributed to either disorder — illustrating the significant criterion overlap between these diagnoses. Her treatment plan must address both conditions simultaneously, as treating only the depression or only the anxiety is unlikely to produce remission.

The Problem of Criterion Overlap

The DSM-5-TR criteria for MDD and GAD share several symptoms: difficulty concentrating, sleep disturbance, fatigue, psychomotor agitation/restlessness, and irritability. This criterion overlap inflates diagnostic comorbidity rates and complicates assessment. Research using structural equation modeling has attempted to disentangle shared versus disorder-specific symptoms, generally finding that anhedonia and sadness are most specific to depression, while autonomic hyperarousal and excessive worry are most specific to anxiety, with a large shared middle ground.

Comorbid anxiety-depression has significant implications for treatment selection, response rates, and the likelihood of achieving remission. Evidence from multiple large-scale trials demonstrates that comorbidity modifies treatment outcomes across pharmacological, psychotherapeutic, and combined modalities.

Pharmacotherapy

SSRIs and SNRIs remain first-line treatments for comorbid anxiety-depression, as they carry regulatory approvals for both MDD and most anxiety disorders. However, treatment response in comorbid presentations is consistently slower and less robust than in single-disorder depression:

• The STAR*D trial demonstrated that anxious depression (defined as a HAM-D anxiety/somatization factor score ≥ 7) was associated with significantly lower remission rates to citalopram (22.2% vs. 33.4% for non-anxious depression), longer time to response, and greater dropout due to side effects.
• Meta-analyses suggest that the number needed to treat (NNT) for antidepressant efficacy in comorbid anxiety-depression is approximately 7–9, compared to approximately 5–7 for uncomplicated MDD.
• SNRIs (venlafaxine, duloxetine) may offer modest advantages over SSRIs in comorbid presentations, likely due to the addition of noradrenergic activity. A meta-analysis by Papakostas et al. found that dual-action agents showed a small but statistically significant advantage (approximately 2–4 percentage points in response rates) over SSRIs in anxious depression, though the clinical significance of this difference is debated.
• Mirtazapine, with its combined noradrenergic and serotonergic mechanism plus antihistaminic sedation, is useful in comorbid presentations featuring severe insomnia and agitation, though weight gain limits tolerability.
• Benzodiazepines provide rapid anxiolysis but do not treat depression and carry significant risks of dependence, cognitive impairment, and rebound anxiety. Guidelines generally recommend against benzodiazepines as monotherapy for comorbid anxiety-depression, though short-term adjunctive use during SSRI/SNRI initiation (the first 2–4 weeks, while serotonergic agents reach efficacy) is a common clinical practice supported by some evidence for faster initial symptom reduction.
• Buspirone augmentation of SSRIs showed modest benefit in the STAR*D trial (approximately 30% remission rate in Level 2 augmentation), with some suggestion of particular benefit in patients with anxious features.

Psychotherapy

Cognitive-behavioral therapy (CBT) has robust evidence for both depression and anxiety disorders independently, and growing evidence supports its use in comorbid presentations. The structure of CBT allows for the integration of techniques targeting both conditions — cognitive restructuring for depressive schemas and anxious threat appraisals, behavioral activation for depressive withdrawal, and graduated exposure for anxiety-driven avoidance.

Transdiagnostic CBT protocols, most notably the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders developed by Barlow and colleagues, were designed specifically to address comorbid emotional disorders through a common set of principles targeting neuroticism and emotional dysregulation. Randomized controlled trials of the Unified Protocol have demonstrated efficacy comparable to single-disorder CBT protocols, with the advantage of addressing multiple comorbid conditions simultaneously.

Meta-analytic evidence indicates that CBT for comorbid anxiety-depression produces moderate-to-large effect sizes (Hedges' g ≈ 0.7–1.0 for primary outcomes), though remission rates are lower than for single-disorder presentations. A Cochrane review of psychological therapies for comorbid anxiety-depression found that CBT was the best-supported modality, with behavioral activation and problem-solving therapy also showing evidence of efficacy.

Combined Treatment

For moderate-to-severe comorbid anxiety-depression, guidelines from the APA, NICE, and CANMAT generally recommend combined pharmacotherapy and psychotherapy. A meta-analysis by Cuijpers et al. (2014) found that combined treatment was superior to either modality alone, with an NNT of approximately 4 for combined versus pharmacotherapy alone and approximately 8 for combined versus psychotherapy alone. The advantage of combined treatment appears most pronounced in more severe presentations and when comorbidity is present.

A central clinical question in managing anxiety-depression comorbidity is whether to treat both conditions simultaneously (integrated approach) or address one condition first and then treat the residual disorder (sequential approach). The evidence, while not definitive, increasingly favors integrated or parallel treatment.

The Case for Integrated Treatment

Integrated treatment addresses both disorders concurrently using either a single treatment with dual efficacy (e.g., an SSRI or transdiagnostic CBT) or parallel treatments targeting each condition. The rationale is based on several observations:

• Mutual maintenance: Anxiety and depression frequently maintain each other through bidirectional mechanisms. Depressive withdrawal reduces opportunities for corrective experiences that could reduce anxiety; avoidance driven by anxiety reduces engagement in rewarding activities, worsening depression. Treating only one condition leaves the maintaining mechanisms of the other intact.
• Shared mechanisms: Given the overlapping neurobiology discussed above, interventions targeting shared substrates (serotonergic function, HPA axis regulation, prefrontal-limbic connectivity) should improve both conditions simultaneously.
• Clinical efficiency: Integrated treatment avoids the delays inherent in sequential approaches, where the second condition may worsen while the first is being treated.

Evidence from randomized trials supports these arguments. Studies of SSRIs and SNRIs in comorbid populations show concurrent improvement in both anxiety and depressive symptom measures, though anxiety symptoms often take longer to reach full response (8–12 weeks versus 4–8 weeks for depressive symptoms). Transdiagnostic CBT protocols produce simultaneous improvement in anxiety and depressive outcomes.

The Case for Sequential Treatment

Some clinicians advocate treating the primary or most functionally impairing condition first, particularly when resource constraints limit access to integrated approaches. The most commonly recommended sequence is to target anxiety first, based on the epidemiological finding that anxiety typically precedes depression and the clinical hypothesis that depression may remit when the underlying anxiety is effectively treated. Some evidence supports this approach: studies show that successful treatment of panic disorder or social anxiety disorder leads to significant improvement in comorbid depressive symptoms in approximately 40–50% of cases, sometimes sufficient to achieve remission of the depressive episode without directly targeting it.

However, when depression is severe, suicidality is present, or functional impairment is dominated by depressive symptoms (profound anhedonia, psychomotor retardation, inability to engage in exposure-based work), prioritizing depression treatment is clinically appropriate.

Stepped Care Models

Contemporary service delivery models, including the collaborative care model validated in the IMPACT trial and the DIAMOND initiative, use measurement-based stepped care that is well-suited to comorbid presentations. Patients are regularly assessed on both anxiety and depressive symptom measures (e.g., PHQ-9 and GAD-7), with treatment adjustments triggered by failure to meet symptom reduction benchmarks. This approach inherently addresses both conditions through iterative treatment optimization. The collaborative care model has demonstrated an NNT of approximately 6 for depression outcomes in primary care, with evidence suggesting comparable benefits for anxiety outcomes.

The presence of comorbid anxiety in depression — and vice versa — is one of the most consistently identified negative prognostic factors in longitudinal outcome studies. This prognostic impact is evident across multiple domains.

Treatment Resistance

Comorbid anxiety is a robust predictor of treatment resistance in depression. The STAR*D data demonstrated that anxious depression was associated with lower remission rates across all four treatment levels, not just the initial citalopram trial. Patients with anxious depression were more likely to require multiple treatment steps and less likely to achieve remission at any individual step. Similar findings emerge from the GENDEP study, where anxiety severity at baseline predicted poorer outcomes to both escitalopram and nortriptyline.

Chronicity and Relapse

Longitudinal studies consistently show that comorbid anxiety-depression follows a more chronic course than either disorder alone. The Harvard/Brown Anxiety Research Program (HARP) found that individuals with comorbid GAD and MDD had significantly lower rates of recovery over 12 years of follow-up compared to those with either condition alone. The Netherlands Study of Depression and Anxiety (NESDA) demonstrated that comorbid anxiety-depression was associated with a chronic or recurrent course in approximately 75% of cases over 6 years, compared to approximately 50% for single-disorder depression.

Functional and Medical Outcomes

Comorbidity predicts worse functional outcomes across occupational, social, and physical health domains. Medical comorbidity is also elevated: the combination of anxiety and depression is associated with increased cardiovascular risk, with meta-analyses demonstrating a hazard ratio of approximately 1.5–1.7 for cardiac events in comorbid anxiety-depression, compared to approximately 1.3 for depression alone. The mechanisms likely involve sustained sympathetic activation, HPA axis dysregulation, inflammation, and behavioral factors (physical inactivity, poor diet, medication non-adherence).

Positive Prognostic Factors

Not all prognostic indicators are negative. Several factors predict better outcomes even in comorbid presentations:

• Younger age at treatment initiation
• Shorter duration of illness before treatment
• Absence of personality disorder comorbidity
• Strong social support
• Adherence to combined pharmacotherapy and psychotherapy
• Early symptom improvement (≥20% reduction in symptom scores by week 4 of treatment), which predicts eventual response and remission even in anxious depression

Given the high bidirectional comorbidity rates, systematic screening for the companion condition whenever one disorder is identified should be considered standard clinical practice. This recommendation is supported by multiple clinical guidelines.

Screening for Anxiety in Depression

When depression is identified, screening for anxiety disorders should be routine. The GAD-7 is a validated, efficient screener for generalized anxiety (sensitivity 89%, specificity 82% at a cutoff of 10) and performs reasonably well as an initial screen for other anxiety disorders, including panic disorder and social anxiety disorder. The Overall Anxiety Severity and Impairment Scale (OASIS) is a brief 5-item transdiagnostic measure that can capture anxiety symptoms across multiple disorders. For specific anxiety disorders, targeted instruments such as the Panic Disorder Severity Scale (PDSS) or the Liebowitz Social Anxiety Scale (LSAS) may be warranted based on clinical suspicion.

Screening for Depression in Anxiety

When an anxiety disorder is identified, screening for depression is equally important. The PHQ-9 (sensitivity approximately 88%, specificity approximately 85% at a cutoff of 10) is the most widely used and validated instrument. The PHQ-2 — a two-item screen asking about depressed mood and anhedonia — can serve as an ultra-brief initial screen (sensitivity approximately 83%, specificity approximately 90%), with positive results followed up by the full PHQ-9.

Integrated Assessment Approach

In practice, dual screening with the PHQ-9 and GAD-7 administered together (combined administration takes approximately 5 minutes) is a practical and evidence-supported approach. This combination captures the core symptom dimensions of both conditions and provides continuous severity measures that can be tracked over time for measurement-based care. Some clinical systems use the PHQ-4, an ultra-brief composite of the PHQ-2 and GAD-2, as an initial screen, with a score ≥ 6 prompting full assessment.

Beyond self-report measures, clinicians should conduct structured or semi-structured diagnostic interviews when comorbidity is suspected. The MINI International Neuropsychiatric Interview (MINI) is a time-efficient structured interview that covers major mood and anxiety diagnoses and is suitable for busy clinical settings.

Clinical Vignette: Screening Uncovers Comorbidity

A 52-year-old man presents to his primary care physician after a workplace panic attack — sudden onset of heart pounding, chest tightness, dizziness, and fear of dying. An emergency department evaluation was negative for cardiac pathology. The physician diagnoses panic disorder and initiates sertraline 50 mg. At follow-up, routine PHQ-9 screening reveals a score of 15, with the patient endorsing depressed mood, anhedonia, fatigue, feelings of worthlessness, and passive suicidal ideation ("I sometimes wonder if my family would be better off without me"). Further assessment confirms comorbid MDD that had been developing insidiously over several months but was overshadowed by the dramatic panic presentation. The treatment plan is adjusted to ensure adequate antidepressant dosing (sertraline titrated to 150 mg), safety planning for suicidal ideation, and referral for CBT addressing both panic and depression.

The high comorbidity between anxiety and depression has driven interest in transdiagnostic models that conceptualize these conditions as related expressions of a shared underlying vulnerability rather than independent disorders.

The Tripartite Model

Clark and Watson's (1991) tripartite model proposed that anxiety and depression share a common factor of negative affectivity (or neuroticism), while being differentiated by physiological hyperarousal (specific to anxiety) and low positive affectivity / anhedonia (specific to depression). This model has received substantial empirical support from factor analytic studies and provides a parsimonious framework for understanding why these conditions co-occur yet remain distinguishable. It also aligns with the neurobiological evidence: negative affectivity maps onto amygdala hyperreactivity and serotonergic dysfunction (shared), while low positive affect maps onto mesolimbic dopamine circuit dysfunction (more depression-specific) and hyperarousal maps onto noradrenergic and autonomic dysregulation (more anxiety-specific).

HiTOP and the Internalizing Spectrum

The Hierarchical Taxonomy of Psychopathology (HiTOP) places anxiety disorders and depressive disorders together within a broad internalizing spectrum, further divided into distress (MDD, GAD, PTSD, dysthymia) and fear (panic disorder, social anxiety, specific phobias, agoraphobia) subfactors. Notably, GAD clusters with depression under the distress subfactor rather than with other anxiety disorders under the fear subfactor, providing a structural explanation for the particularly high comorbidity between GAD and MDD.

DSM-5-TR: The "Anxious Distress" Specifier

The DSM-5-TR includes an "anxious distress" specifier for major depressive episodes, acknowledging the clinical significance of anxiety symptoms within depression even when a separate anxiety disorder diagnosis is not warranted. The specifier requires at least two of: feeling keyed up or tense, unusual restlessness, difficulty concentrating due to worry, fear of something awful happening, and feeling of potential loss of control. Severity is rated mild (2 symptoms), moderate (3 symptoms), or severe (4–5 symptoms). This specifier was added specifically because anxious distress in depression is associated with greater suicidality, longer illness duration, and poorer treatment response — essentially incorporating the prognostic data discussed above into the diagnostic framework.

ICD-11 Mixed Depressive and Anxiety Disorder

The ICD-11 includes a specific diagnostic category for mixed depressive and anxiety disorder (6A73), applicable when symptoms of both depression and anxiety are present but neither reaches the threshold for an independent diagnosis. This category recognizes a large population of patients — particularly in primary care — who experience clinically significant distress and impairment from subthreshold mixed symptoms. Prevalence estimates for this mixed presentation range from 1–5% of the general population and substantially higher in primary care settings.

Anxiety-depression comorbidity presents unique challenges in specific populations that merit distinct clinical consideration.

Children and Adolescents

Anxiety disorders are among the earliest-onset psychiatric conditions, with median onset in childhood (age 6 for specific phobias, age 11 for social anxiety disorder). Depression onset peaks in adolescence. The overlap is substantial: among adolescents with MDD, approximately 40–70% meet criteria for a comorbid anxiety disorder. Longitudinal data from the Great Smoky Mountains Study and similar cohorts confirm that childhood anxiety disorders predict adolescent depression. Treatment evidence supports CBT (particularly the Coping Cat protocol and its adaptations) and SSRIs (fluoxetine has the strongest evidence base in pediatric populations), with the combination outperforming either alone in the Treatment of Adolescent Depression Study (TADS) and the Child/Adolescent Anxiety Multimodal Study (CAMS).

Older Adults

In geriatric populations, anxiety-depression comorbidity is common (estimated at 30–50% of depressed older adults) and frequently presents with prominent somatic symptoms, cognitive complaints mimicking dementia ("pseudodementia"), and worry focused on health and mortality. The IMPACT trial demonstrated that collaborative care was effective for late-life depression, including in patients with comorbid anxiety. Pharmacotherapy in older adults requires attention to drug interactions, fall risk with benzodiazepines, and the anticholinergic burden of certain antidepressants.

Perinatal Populations

Comorbid perinatal anxiety and depression affects approximately 8–13% of pregnant and postpartum individuals. Screening with the Edinburgh Postnatal Depression Scale (EPDS) captures depressive symptoms but may underdetect anxiety; adding the GAD-7 improves identification. Untreated comorbidity poses risks to both parent and infant, including preterm birth, impaired bonding, and developmental effects. Treatment decisions must weigh pharmacological risks during pregnancy and lactation against the well-documented risks of untreated illness.